uniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 30,000 Shares

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 30,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the transaction, the insider owned 148,235 shares of the company’s stock, valued at approximately $6,881,068.70. This represents a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, June 26th, Walid Abi-Saab sold 1,434 shares of uniQure stock. The shares were sold at an average price of $46.86, for a total transaction of $67,197.24.
• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00.

uniQure Trading Down 7.4%

Shares of QURE stock opened at $41.81 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market cap of $2.64 billion, a PE ratio of -12.01 and a beta of 0.90. The company has a 50-day moving average of $30.05 and a two-hundred day moving average of $23.73. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. On average, analysts predict that uniQure N.V. will post -3.63 EPS for the current year.

Institutional Trading of uniQure

A number of large investors have recently modified their holdings of QURE. Torren Management LLC acquired a new position in uniQure during the 4th quarter worth $28,000. IFP Advisors Inc acquired a new stake in uniQure in the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC acquired a new stake in uniQure in the 4th quarter valued at about $48,000. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the 3rd quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after buying an additional 906 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on QURE shares. Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th. Royal Bank Of Canada raised their price target on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research note on Wednesday, June 17th. Leerink Partners boosted their price objective on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Mizuho increased their target price on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $64.17.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $80 price target while raising multiple earnings estimates for uniQure, including near- and longer-term forecasts. The improved outlook suggests analysts see stronger future profitability than before. uniQure analyst update
• Positive Sentiment: Recent technical coverage highlighted that QURE is trading above a golden cross, which traders often view as a bullish momentum signal and a possible support level. Zacks golden cross article
• Neutral Sentiment: Media attention also included a comparison piece on uniQure versus Viridian Therapeutics and a short-squeeze watchlist mention, which may be adding trading interest but does not directly change fundamentals. AAII comparison article
• Negative Sentiment: Director Jack Kaye and insider Walid Abi-Saab both sold shares in recent SEC filings. Although the trades were made under pre-arranged 10b5-1 plans, insider selling can still weigh on sentiment. Jack Kaye SEC filing Walid Abi-Saab SEC filing

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.